Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Radiation therapy works by using high-energy X-rays to kill cancer cells. MSK offers precise radiation therapy that kills throat cancer cells with fewer side effects from radiatio ...
“Incorporating ctDNA into the decision-making process helps refine who can safely keep their bladder,” Ghatalia, associate professor, Department of Hematology/Oncology, at Fox Chase Cancer Center in ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
At a median follow-up of 145.1 months, the 10-year overall survival rate was 28.3% with chemoradiotherapy boost and 29.9% with surgery. Long-term survival following chemoradiation is comparable to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results